July 23, 2025 4:32pm

How long will the upside stay in the portfolio or will these “animal spirits” drive “uncle algo and his electronic trading dwarfs” to take action when faced with high levels of volatility in this market?

When I see these highs, I say BYE especially with earnings on July’s next week’s tail end

Never above you. Never below you. Always beside you … I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  

My perspective is retail investors should roll-the-dice with econ readings until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

Wednesday’s RegMed Investors’ (RMi) pre-open: Optimism amplifies … https://www.regmedinvestors.com/articles/14009

Tuesday night’s RegMed Investors (RMi) Closing Bell: Cause and effect, reaping what was sown … https://www.regmedinvestors.com/articles/14008

RegMed Investors (RMi) Research Note: Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The Dow closed UP +507.85 points or +1.14%, the S&P closed UP +49.33 points or +0.78% while the Nasdaq closed UP +127.33 points or +0.61%

  • Theme of the session, trade developments spurred optimism

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • Home sales in June were flat compared with a year ago. There were 1.53 million units for sale at the end of June, an increase of 15.9% year over year. Home prices in June hit a record high for the month. High mortgage rates are causing home sales to remain stuck at cyclical lows. The average rate now is 6.77%.

Wednesday’s advance/decline line opened positive with 22 incliners, 9 decliners and 4 flats ending with a positive close of 30 incliners, 1 decliners and 4 flats        

Metrics:  Wednesday, the IBB was up +2.57%, the XBI was up +1.56% while the VIX was down -1.04 points or -6.30% at 15.46

 

Q3 – 7/25 – 1 market holiday, 12 positive and 4 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Wednesday Closing UP (10 of 30) +$ after Tuesday’s

  • Vericel (VCEL +$2.37 after Tuesday’s +$2.52 after Monday’s +$0.12),
  • CRISPR Therapeutics (CRSP +$2.21 after Tuesday’s +$0.60 after Monday’s +$0.20),
  • Moderna (MRNA +$1.94 after Tuesday’s +$1.76 after Monday’s -$0.29)
  • Ultragenyx Pharmaceuticals (RARE +$1.57),
  • uniQure NV (QURE +$1.13 after Tuesday’s -$0.25 after Monday’s -$0.49),
  • BioLife Solutions (BLFS +$1.04 after Tuesday’s +$0.65 after Monday’s $0.07),
  • Mesoblast (MESO +$1.01 after Tuesday’s +$0.43 after Monday’s -$0.97),
  • AxoGen (AXGN +$0.92 after Tuesday’s +$0.93 after Monday’s +$0.33),
  • Intellia Therapeutics (NTLA +$0.75 after Tuesday’s +$0.86 after Monday’s +$0.57),
  • Beam Therapeutics (BEAM +$0.62 after Tuesday’s +$0.51 after Monday’s +$0.28),

Flat (4)

  • bluebird bio (BLUE) P/E acquired
  • Blueprint Medicine (BPMC) acquired by SNY
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)

Wednesday’s Closing DOWN (1 of 1): 

  • Agenus (AGEN -$0.05),

 

The BOTTOM LINE: Cell and gene therapy sector equities within indexes upped their winnings Wednesday amid news of a U.S.-Japan trade deal and progress in talks with the EU.

  • Small caps on the Russell 2000 climbed 1.2%.
  • This could always prove another head fake, but small capitalization U.S. stocks have recently been beating their large cap brethren. Wednesday, the Russell 2000 index of small stocks was beating the S&P 500 so far this week 1.57% to 0.9%. Over the 7 days, the Russell is higher by 2.17%, better than the S&P 500′s 1.44% gain.
  • Volume was higher on both the Nasdaq and NYSE compared with Tuesday.

 

The cell and gene therapy sector closed Wednesday (7/23), Tuesday and Monday positive

  • After slipping last Friday (7/18) following a positive close on last Thursday and Wednesday having slid on Tuesday after Monday’s positive close
  • And popping on the previous Friday, Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday ….
  • After the previous, previous week’s pop on multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

 

Earnings are a’comin: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA), 8/5, Tuesday = AxoGen (AXGN)

 

As I also wrote, the “June Swoon” is over … however, July is becoming better than other months. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

 July evolves: understand the “flow” …

  • 7/23 – Wednesday closed positive with 30 positive, 1 negative and 4 flats
  • 7/22 – Tuesday closed positive with 19 positive, 10 negative and 6 flats
  • 7/21 – Monday closed positive with 17 positive, 14 negative and 4 flats

Last week:

  • 7/18 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 – Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

The previous week:

  • 7/11 - Friday closed negative with 5 positive, 28 negative and 2 flats
  • 7/10 - Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating different versions of ranking, so investors can make the connection …

The top three (3) performing in the session:   

  • Wednesday: Vericel (VCEL), CRISPR Therapeutics (CRSP) and Moderna (MRNA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Moderna (MRNA)
  • Monday: CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY) and Intellia Therapeutics (NTLA)
  • Friday: CRISPR Therapeutics (CRSP), Mesoblast (MESO) and Solid Biosciences (SLDB)

The worst three (3) in the session: 

  • Wednesday: Agenus AGEN) and Brainstorm Cell Therapeutics (BCLI)
  • Tuesday: Lenz Pharmaceuticals (LENZ), Precigen (PGEN) and uniQure NV (QURE)
  • Monday: Mesoblast (MESO), Vericel (VCEL) and uniQure NV (QURE)
  • Friday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Ultragenyx Pharmaceuticals RARE)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.